Polaryx Therapeutics, Inc. PLYX Deferred Tax Assets, Valuation Allowance

Deferred Tax Assets, Valuation Allowance at other companies

State StreetSTT

$198M+15.1%

PepsiCoPEP

$6.12B-1.1%

Imperial OilIMO

$65M-1.5%

AmetekAME

$33.55M+57.5%

Mondelez InternationalMDLZ

$1.45B+12.2%

The Travelers CompaniesTRV

$38M+8.6%

Operating income-$2.0M+61.2%

Net income-$2.5M+49.6%

EPS (diluted)-$0.05+54.5%

Cash & equivalents$3.1M+1,132%

Total equity$2.5M-41.5%

Total assets$3.5M—

Operating cash flow-$2.1M-191%

Market cap$115.64M—

Return on equity-1,209.8%—

Current ratio3.5×—

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.

The official record: Polaryx Therapeutics, Inc. ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Polaryx Therapeutics, Inc. 's deferred tax assets, valuation allowance?: Polaryx Therapeutics, Inc. (PLYX) reported deferred tax assets, valuation allowance of $6.39M in Q4 2025.